Clinical Criteria
ADD/ADHD Agents (Revised March 21, 2019)*
Alinia (Revised March 21, 2019)*
Aliskiren Containing Agents (Revised March 21, 2019)*
Allergen Extracts (Revised March 21, 2019)*
Altabax (Revised March 21, 2019)*
Androgenic Agents (Pending Implementation) (Revised March 21, 2019)*
Antiemetic Agents (Revised March 21, 2019)*
Antipsychotic Agents (Revised March 22, 2019)*
Anxiolytics and Sedative-Hypnotics (Revised March 22, 2019)*
Buprenorphine Agents (Revised March 22, 2019)*
Carisoprodol Overuse (Revised March 26, 2019)*
Carisoprodol-Containing Agents (Pending Implementation) (Revised March 26, 2019)*
CGRP Antagonists (Pending Implementation) (Revised March 26, 2019)*
Colcrys (Pending Implementation) (Revised March 26, 2019)*
Copaxone (Pending Implementation) (Revised March 26, 2019)*
Cough & Cold (Revised March 26, 2019)*
COX-2 Inhibitors (Revised March 26, 2019)*
Cyclobenzaprine (Revised March 27, 2019)*
Cymbalta (Revised March 27, 2019)*
Cystic Fibrosis Agents (Revised March 27, 2019)*
Cytokine and CAM Antagonists (Pending Implementation) (Revised March 27, 2019)*
Cytokine and CAM Antagonists (Revised March 27, 2019)*
Desmopressin (Revised March 27, 2019)*
Dextromethorphan Overutilization (Revised March 27, 2019)*
Diabetic Test Strips (Pending Implementation) (Revised March 27, 2019)*
Diclofenac (Pending Implementation) (Revised March 27, 2019)*
DPP4 Inhibitors (Revised March 27, 2019)*
Drug Regimen Optimization (Revised April 3, 2015)*
Dupixent (Revised March 28, 2019)*
Duplicate Therapy (Revised March 27, 2019)*
Emflaza (Revised March 28, 2019)*
Enzymes (Pending Implementation) (Revised March 28, 2019)*
Epidiolex (Pending Implementation) (Revised March 28, 2019)*
Erythropoiesis-Stimulating Agents (Revised March 28, 2019)*
Fentanyl Agents (Revised March 28, 2019)*
Forteo (Pending Implementation) (Revised March 28, 2019)*
Gabapentin Agents (Revised March 29, 2019)*
Gaucher's Disease Agents (Pending Implementation) (Revised March 29, 2019)*
GI Motility Agents (Revised March 29, 2019)*
GLP-1 Receptor Agonists (Revised March 29, 2019)*
Growth Hormone Agents (Pending Implementation) (Revised March 29, 2019)*
Growth Hormone Agents (Revised March 29, 2019)*
Growth Hormone Quick Reference Guide
HAE Agents (Pending Implementation) (Revised March 29, 2019)*
HP Acthar (Revised March 29, 2019)*
Imiquimod (Revised March 29, 2019)*
Increlex (Revised March 29, 2019)*
Injectable Agents for PAH (Pending Implementation) (Revised March 29, 2019)*
Ketorolac (Revised March 29, 2019)*
Keveyis (Pending Implementation) (Revised March 29, 2019)*
Leukotriene Modifiers (Revised March 29, 2019)*
Lidoderm (Pending Implementation) (Revised March 29, 2019)*
Lovaza (Revised March 29, 2019)*
Lyrica (Pending Implementation) (Revised March 29, 2019)*
Makena (Revised March 29, 2019)*
Morphine Milligram Equivalent Criteria (Revised March 29, 2019)*
Nuedexta (Revised March 29, 2019)*
Nuplazid (Pending Implementation) (Revised March 29, 2019)*
Opiate Overutilization (Revised March 29, 2019)*
Opiate/Benzodiazepine/Muscle Relaxant Combinations (Revised March 29, 2019)*
Orilissa (Pending Implementation) (Revised March 29, 2019)*
Oxycontin / Narcotic Analgesic (Revised March 29, 2019)*
PCSK9 Inhibitors (Revised March 29, 2019)*
Phosphate Binders (Revised March 29, 2019)*
Plavix (Pending Implementation) (Revised March 29, 2019)*
Promethazine Utilization (Revised March 29, 2019)*
Propylthiouracil (Revised March 29, 2019)*
Proton Pump Inhibitors (Pending Implementation) (Revised March 29, 2019)*
Provigil and Nuvigil (Revised March 29, 2019)*
Ranexa (Revised March 29, 2019)*
Revatio (Revised March 29, 2019)*
Savella (Pending Implementation) (Revised March 29, 2019)*
SGLT2 Inhibitor Combination Agents (Pending Implementation) (Revised March 29, 2019)*
Symlin (Revised March 29, 2019)*
Synagis (Revised March 29, 2019)*
Thiazolidinediones (Revised March 29, 2019)*
Topical Acne Agents (Pending Implementation) (Revised March 29, 2019)*
Topical Immunomodulators (Revised March 29, 2019)*
Topical Retinoids (Pending Implementation) (Revised March 29, 2019)*
Valturna (Retired) (Revised August 23, 2017)*
VMAT2 Inhibitors (Revised March 29, 2019)*
Xifaxan (Revised March 29, 2019)*
Xyrem (Pending Implementation) (Revised March 29, 2019)*
Xyrem (Revised March 29, 2019)*
Zelboraf (Pending Implementation) (Revised March 29, 2019)*
1 - 85
Announcements
Agenda for April Drug Utilization Review Board Meeting Available
by CHRISTINA.FAULKNER on 04/12/2019
The agenda for the Texas Drug Utilization Review Board meeting on Friday, April 26 is now available from the Vendor Drug Program website at www.txvendordrug.com/resources/drug-utilization-review-board. Also available are instructions for submitting written materials to the board prior to the meeting and testifying on the day of the meeting.